Vitality Watch

Dossier clinicaltrials trial early 28-sep-2026
Small or early-phase human trial or pilot study

Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging

Key claim: A clinical trial is testing whether 9 months of 5 mg OTC melatonin improves Alzheimer’s disease biomarkers and cognitive function in adults with and without mild cognitive impairment.

Abstract

The study will examine whether 5mg melatonin (over the counter, OTC) over a 9-month period improves Alzheimer’s disease (AD) biomarkers and cognitive function in two groups of individuals: those with mild cognitive impairment (MCI+) and those who are not (MCI-). AD biomarkers will be measured from cerebrospinal fluid (CSF) obtained from lumbar punctures. Cognitive function will be evaluated with routine neuropsychological tests.

AS OF AUGUST 2024, THE LUMBAR PUNCTURE PROCEDURES FOR THIS CLINICAL TRIAL HAVE BEEN ELIMINATED. THAT IS, PARTICIPANTS ARE NO LONGER RECEIVING A LUMBER PUNCTURE. BUT ARE CONTINUING TO RECEIVE TWO SEPARATE BLOOD DRAWS FOR BIOMARKER TESTING.

Why this matters

A clinical trial is testing whether 9 months of 5 mg OTC melatonin improves Alzheimer’s disease biomarkers and cognitive function in adults with and without mild cognitive impairment.

Source

Link

Briefing card

Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
Stage: trial early · clinicaltrials · 28-sep-2026

A clinical trial is testing whether 9 months of 5 mg OTC melatonin improves Alzheimer's disease biomarkers and cognitive function in adults with and without mild cognitive impairment.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT03954899

build build 880 · 2bcef25 · 2026-11-18